<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="185456">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679601</url>
  </required_header>
  <id_info>
    <org_study_id>AN2690-ONYC-205</org_study_id>
    <nct_id>NCT00679601</nct_id>
  </id_info>
  <brief_title>Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)</brief_title>
  <official_title>An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients With Moderate to Severe Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the absorption and systemic pharmacokinetics of
      AN2690 following daily application to all ten (10) toenails for 28 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single center, open-label, multiple-dose study design will be used. Planned enrollment is
      20 subjects to complete 15. Subjects must have a clinical diagnosis of onychomycosis of each
      great toenail and a clinical diagnosis of onychomycosis of six of the remaining toenails.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of AN2690 in plasma and the concentration of AN2690 in urine over time</measure>
    <time_frame>Days 0, 1, 14, 15, and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy measures of linear toenail growth, fungal culture results, KOH results, and clear toenail growth</measure>
    <time_frame>Days 0, 14, 28, and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance assessed by application site reactions, adverse events, vital signs, physical examinations, and 12-lead EKG</measure>
    <time_frame>Days 0-28, and 42</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Onychomycosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2690</intervention_name>
    <description>AN2690 7.5% Solution, once daily for 28 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥18 and ≤65

          -  BMI between 18.5 and 35 inclusive

          -  Moderate to severe onychomycosis involving ≥80% of both great toenails, as determined
             by visual inspection after the nail has been trimmed

          -  Combined thickness of the nail plate and nail bed of each great toenail is &gt;3mm

          -  At least 6 additional toenails with a clinical diagnosis of onychomycosis

          -  If a female of childbearing potential, must be using of a highly effective method of
             birth control or abstinence and be willing to remain on that same method of birth
             control throughout the study

          -  Capable of understanding and signing the informed consent, and willing to comply with
             all requirements of the study

        Exclusion Criteria:

          -  History of allergy to any of the study drug or any components in the test product(s)
             or history of hypersensitivity or allergic reactions to any of the study preparations
             as described in the Investigator's Brochure

          -  Clinically significant laboratory abnormalities that would interfere with the conduct
             or interpretation of the study or jeopardize his/her safety

          -  Diabetes mellitus requiring treatment other than diet and exercise

          -  Willing to refrain from the use of nail cosmetics such as clear and or colored nail
             lacquers from the screening visit until the end of the study

          -  Nursing, pregnant or planning to become pregnant during the study

          -  Failure to complete the specified washout period(s) for the following topical:

               1. Topical antifungal applied to the feet (does not include antifungals for
                  treatment of T. pedis during the study): 4 weeks

               2. Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks

          -  Failure to complete the specified washout period(s) for the following systemic
             medications:

               1. Corticosteroids (including intramuscular injections): 2 weeks

               2. Antifungals for treatment of onychomycosis or any systemic antifungal with known
                  activity against dermatophyte: 24 weeks

               3. Systemic immunomodulators: 4 weeks

          -  Received treatment of any type for cancer within the last 6 months

          -  History of any significant internal disease

          -  Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary
             disorders, onychogryphosis, trauma to the nail(s) to be treated

          -  AIDS or AIDS related complex

          -  History of street drug or alcohol abuse

          -  Donated or lost blood, or participated in a clinical study which involved the
             withdrawal of a large volume of blood (480 mL or more), during the six-week period
             preceding study initiation

          -  Donated plasma during the two week period preceding study initiation

          -  Participated in any other trial of an investigational drug or device within 30 days
             prior to enrollment or participation in a research study concurrent with this study

          -  Prior enrollment in a study using the study drug, AN2690
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Beutner, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>J&amp;S Studies</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <lastchanged_date>May 15, 2008</lastchanged_date>
  <firstreceived_date>May 15, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Karl Beutner, MD, PhD, Chief Medical Officer</name_title>
    <organization>Anacor Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Onychomycosis</keyword>
  <keyword>Fungal Nail</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tavaborole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
